Dr. Gomella Discusses Interdisiplinary Treatment

Experts shared the key data that stood out in GU oncology at the 2026 ASCO Annual Meeting.

The FDA approved a bioequivalent formulation of olaparib for use in previously approved cancer indications.

Experts shared the key data that stood out in hematologic oncology at the 2026 ASCO Annual Meeting.

The TRIPP-FFX trial met its primary end points of local disease control and safety with P-32 microparticles plus FOLFIRINOX pancreatic adenocarcinoma.

Readouts across LBCL, relapsed/refractory myeloma, and CALR-mutated myelofibrosis anchored the hematology data presented at EHA 2026.

Mark Garzotto, MD, discusses data with aglatimagene besadenovec plus valacyclovir and EBRT in intermediate- to high-risk localized prostate cancer.

In case you missed any, check out our recap of the episodes of OncLive On Air that aired in June 2026.

GE HealthCare and Mayo Clinic announced a novel theranostics study to explore a personalized approach to radioligand therapy for advanced prostate cancer.